Open AccessInhibition of type 5 phosphodiesterase counteracts β2-adrenergic signalling in beating cardiomyocytes
Author(s) -
Andrea M. Isidori,
Marisa Cornacchione,
Federica Barbagallo,
Antonio Di Grazia,
Florencia Barrios,
Lorenzo Fassina,
Lucia Monaco,
Elisa Giannetta,
Daniele Gianfrilli,
Silvio Garofalo,
Xiaoxiao Zhang,
Xiongwen Chen,
Yang Xiang,
Andrea Lenzi,
Manuela Pellegrini,
Fabio Naro
Publication year - 2015
Publication title -
cardiovascular research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.774
H-Index - 219
eISSN - 1755-3245
pISSN - 0008-6363
DOI - 10.1093/cvr/cvv123
Subject(s) - phosphodiesterase , phosphodiesterase 3 , cgmp specific phosphodiesterase type 5 , medicine , endocrinology , pde10a , chemistry , stimulation , contractility , microbiology and biotechnology , adrenergic receptor , receptor , biology , sildenafil , biochemistry , enzyme
Compartmentalization of cAMP and PKA activity in cardiac muscle cells plays a key role in maintaining basal and enhanced contractility stimulated by sympathetic nerve activity. In cardiomyocytes, activation of adrenergic receptor increases cAMP production, which is countered by the hydrolytic activity of selective phosphodiesterases (PDEs). The intracellular regional dynamics of cAMP production and hydrolysis modulate downstream signals resulting in different biological responses. The interplay between beta receptors (βARs) signalling and phosphodiesterase 5 (PDE5) activity remains to be addressed.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom